# A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

> **NCT06307431** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 272 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Intismeran autogene
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06307431
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2028-01-08
- **Final completion:** 2032-06-08
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307431, "A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06307431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*